Condition Directory

Prostate Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 7, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3916

Shown on this page

Current sort

How Prostate Cancer studies are organized in the registry

Prostate cancer studies are organized around disease-state vocabulary more than most cancers: “castration-resistant” (CRPC), “hormone-sensitive,” and “biochemical recurrence” mark distinct study populations and appear directly in listings. Active-surveillance research is typically registered as observational, so the study-type filter separates it cleanly.

Terms that often appear in related listings

castration-resistant CRPC hormone-sensitive biochemical recurrence

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 769–780 of 3,916 matching trials for Prostate Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Enzalutamide, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Magnetic Resonance Imaging, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Stage IV Bladder Urothelial Carcinoma, Prostate Cancer, Urothelial Carcinoma
Interventions: Computed Tomography, Laboratory Biomarker Analysis, Pembrolizumab, Positron Emission Tomography, Recombinant EphB4-HSA Fusion Protein; Procedure · Other · Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • Newport Beach, California + 5 more

Conditions: Prostate Cancer
Interventions: Focal One high intensity focused ultrasound device; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Advanced Solid Tumor
Interventions: CX-5461; Drug
Lead sponsor: Senhwa Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Santa Monica, California • Tampa, Florida • Boston, Massachusetts + 3 more

Conditions: Prostate Cancer
Interventions: Post (video) about prostate cancer, Post (text post) about prostate cancer, Survey; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years and older
Enrollment: 3,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Prostate Cancer
Interventions: Biopsy; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Health Status Unknown, Elevated PSA
Interventions: Biopsy of Prostate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, MRI Ultrasound Fusion Guided Biopsy; Procedure · Other · Diagnostic Test
Lead sponsor: University of Southern California; Other
Eligibility: 40 Years and older · Male only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 1 more

Conditions: Prostate Cancer Adenocarcinoma
Interventions: 30Gy (Gray) planning target volume (PTV); Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Colorado Springs, Colorado + 5 more

Conditions: Breast Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Interventions: dietary intervention, nutritional support, laboratory biomarker analysis; Dietary Supplement · Procedure · Other
Lead sponsor: University of Southern California; Other
Eligibility: 19 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Newport Beach, California • Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: ARN-509 (Phase 1), ARN-509 (Phase 2); Drug
Lead sponsor: Aragon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 15
States / cities: San Diego, California • San Francisco, California • Atlanta, Georgia + 12 more

Conditions: Advanced Metastatic Castration Resistant Prostate Cancer
Interventions: INV-9956; Drug
Lead sponsor: Shenzhen Ionova Life Sciences Co., Ltd.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Scottsdale, Arizona • Newport Beach, California • Orange, California + 4 more

Conditions: Prostate Cancer
Interventions: Sacituzumab Govitecan; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 3
States / cities: New York, New York • Madison, Wisconsin

About this Prostate Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Prostate Cancer clinical trials

How Prostate Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

High Intensity Focused Ultrasound in Prostate Cancer

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Perspectives About Online Information

Tumor Microenvironment Analysis of Prostate Cancer Metastasis

Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA

Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)

Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

About this Prostate Cancer clinical trials directory page